3 Stocks Under $2 Insiders Are Buying
3 Stocks Under $2 Insiders Are Buying
US crude oil futures traded higher on Wednesday. Investors, meanwhile, focused on some notable insider trades.
美國原油期貨週三走高。與此同時，投資者關注的是一些值得注意的內幕交易。
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
當內部人士買賣股票時，這表明了他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易員可以在他們的整體投資或交易決策中考慮這一因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3
以下是最近幾筆值得注意的細價股內幕交易。有關更多信息，請查看Benzinga的內幕交易平臺。
TRACON Pharmaceuticals
TRACON製藥公司
- The Trade: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) President and CEO Charles Theuer acquired a total of 2,500 shares at an average price of $1.97. To acquire these shares, it cost $4.92 thousand.
- What's Happening: The company is expected to release quarterly earnings after the closing bell today.
- What TRACON Pharmaceuticals Does: TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States.
- 行業： TRACON製藥公司納斯達克(Sequoia Capital：TCON)總裁兼首席執行官查爾斯·休伊爾以1.97美元的平均價格收購了總計2,500股票。收購這些股份，花費了49萬2千美元。
- 正在發生的事情：預計該公司將在今天收盤後發佈季度收益。
- TRACON製藥公司的業務：TRACON製藥公司是一家生物製藥公司，專注於癌症新型靶向療法的開發和商業化，並利用其具有成本效益的合同研究組織(CRO)獨立產品開發平臺與前美國公司合作，在美國開發和商業化創新產品。
Compass Therapeutics
指南針治療公司
- The Trade: Compass Therapeutics, Inc. (NASDAQ:CMPX) CEO Thomas J Schuetz acquired a total of 27,836 shares at an average price of $1.80. The insider spent around $50.1 thousand to buy those shares.
- What's Happening: Compass Therapeutics posted a Q1 loss of $0.07 per share.
- What Compass Therapeutics Does: Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies.
- 《貿易》: 羅盤治療公司納斯達克(Sequoia Capital：CMPX)首席執行官託馬斯·J·舒茨以1.8美元的平均價格收購了27,836股票。這位內部人士花了大約5010萬美元購買了這些股票。
- 發生了什麼事？：Compass治療公司公佈第一季度每股虧損0.07美元。
- 羅盤治療公司是做什麼的：Compass治療公司是一家臨牀階段的生物製藥公司，開發專有抗體療法，旨在利用免疫系統治療實體腫瘤和血液惡性腫瘤。
Also check this: Executives Buy More Than $90M Of 4 Stocks
再來看看這個：高管們購買了4只股票，價值超過9000萬美元
Don't forget to check out our premarket coverage here .
別忘了在這裏查看我們的售前報道。
Invesco Mortgage Capital
景順抵押資本
- The Trade: Invesco Mortgage Capital Inc. (NYSE:IVR) President Kevin Collins acquired a total of 7,178 shares at an average price of $1.67. To acquire these shares, it cost around $11.99 thousand.
- What's Happening: The company recently posted upbeat quarterly earnings.
- What Invesco Mortgage Capital Does: Invesco Mortgage Capital Inc is an REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans.
- 《貿易》: 景順抵押貸款資本公司。(紐約證券交易所代碼：IVR)總裁凱文·柯林斯以1.67美元的平均價格收購了總計7178股股票。收購這些股份的成本約為11.99萬美元。
- 發生了什麼事？：該公司最近公佈了樂觀的季度收益。
- 景順抵押貸款資本的業務：Invesco Mortgage Capital Inc.是一家房地產投資信託基金，投資、融資和管理住宅和商業抵押貸款支持證券和抵押貸款。
譯文內容由第三人軟體翻譯。